Agios Pharmaceuticals Inc (NASDAQ:AGIO) CEO Sells $4,463,409.60 in Stock

Agios Pharmaceuticals Inc (NASDAQ:AGIO) CEO David P. Schenkein sold 49,374 shares of the business’s stock in a transaction that occurred on Wednesday, May 23rd. The shares were sold at an average price of $90.40, for a total value of $4,463,409.60. Following the completion of the sale, the chief executive officer now owns 49,374 shares of the company’s stock, valued at $4,463,409.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Agios Pharmaceuticals traded up $1.44, hitting $93.74, during trading on Thursday, according to MarketBeat Ratings. 315,793 shares of the stock traded hands, compared to its average volume of 505,082. The company has a market cap of $5.35 billion, a P/E ratio of -13.89 and a beta of 2.00. Agios Pharmaceuticals Inc has a twelve month low of $49.76 and a twelve month high of $97.59.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Friday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.03). The company had revenue of $8.80 million for the quarter, compared to analyst estimates of $11.93 million. Agios Pharmaceuticals had a negative return on equity of 61.70% and a negative net margin of 822.32%. The firm’s quarterly revenue was down 16.2% on a year-over-year basis. During the same quarter last year, the company posted ($1.56) earnings per share. equities analysts expect that Agios Pharmaceuticals Inc will post -6.51 earnings per share for the current year.

Several brokerages recently issued reports on AGIO. Piper Jaffray Companies reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 4th. Citigroup began coverage on Agios Pharmaceuticals in a research note on Wednesday, May 23rd. They issued a “buy” rating and a $117.00 price target for the company. SunTrust Banks set a $115.00 price target on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, May 7th. Cann restated a “hold” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, April 17th. Finally, Oppenheimer downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 14th. They noted that the move was a valuation call. Four analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $95.55.

Large investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Agios Pharmaceuticals by 41.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 762 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in shares of Agios Pharmaceuticals during the fourth quarter worth $160,000. S&CO Inc. acquired a new position in shares of Agios Pharmaceuticals during the first quarter worth $278,000. Bank of Montreal Can increased its holdings in shares of Agios Pharmaceuticals by 74.8% during the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 1,520 shares in the last quarter. Finally, M&T Bank Corp acquired a new position in shares of Agios Pharmaceuticals during the first quarter worth $293,000. Institutional investors own 94.30% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Ruptured Biceps Tendon Ends Miguel Cabrera’s Season
Ruptured Biceps Tendon Ends Miguel Cabrera’s Season
Dodgers Getting Big Unexpected Lift from Three Players
Dodgers Getting Big Unexpected Lift from Three Players
What does legal betting mean for the baseball industry?
What does legal betting mean for the baseball industry?
Dodgers Use Nine Pitchers in Nine-Inning Game
Dodgers Use Nine Pitchers in Nine-Inning Game
Max Scherzer Throws Second Career Immaculate Inning
Max Scherzer Throws Second Career Immaculate Inning
Phillies Swept and Jake Arrieta Upset
Phillies Swept and Jake Arrieta Upset


Leave a Reply

 
© 2006-2018 BBNS.